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1 
2 
3 ABSTRACT 
4 
5 
6 Despite their physiological importance, selective interactions between Nuclear Receptors 
7 
8 (NRs) and their cofactors are poorly understood. Here we describe a novel signature motif 
9 
10 (F/YSXXLXXL/Y) in the developmental regulator BCL11A that facilitates its selective 
11 
12 interaction with members of the NR2E/F subfamily. Two copies of this motif (named here as 
13 
14 RID1 and RID2) permit BCL11A to bind COUP-TFs (NR2F1;NR2F2;NR2F6) and 
15 
16 Tailless/TLX (NR2E1), whereas RID1, but not RID2 binds PNR (NR2E3). We confirmed the 
17 
18 existence of endogenous BCL11A/TLX complexes in mouse cortex tissue. No interactions of 
19 
20 RID1 and RID2 with twenty other LBDs from different NR subtypes were observed. We show 
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43 
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that RID1 and RID2 are required for BCL11A-mediated repression of endogenous γ-globin 
gene and the regulatory non-coding transcript Bgl3, and we identify COUP-TFII binding sites 
within the Bgl3 locus. In addition to their importance for BCL11A function, we show that 
F/YSXXLXXL/Y motifs are conserved in other NR cofactors. A single FSXXLXXL motif in the 
NR-binding SET domain protein NSD1 facilitates its interactions with the NR2E/F subfamily. 
However, the NSD1 motif incorporates features of both LXXLL and FSXXLXXL motifs, giving 
it a distinct NR-binding pattern in contrast to other cofactors. In summary, our results provide 
new insights into the selectivity of NR/cofactor complex formation. 
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selective (e.g. Moses (6)) NR binding preferences, surprisingly little is known regarding how 
such molecular selectivity is achieved. 
1 
2 
3 INTRODUCTION 
4 
5 
6 Nuclear Receptors (NRs) are structurally dynamic proteins that selectively recruit 
7 
8 coactivators and corepressors to regulate gene expression. Docking of selected cofactors 
9 
10 with the NR ligand binding domains (LBDs) is mediated by LXXLL (1,2) and CoRNR box 
11 
12 signature motifs (3-5). Reports in the literature have identified potentially several hundred 
13 
14 cofactors that bind one or more of the 48 known human NRs (www.NURSA.org). While 
15 
16 some cofactors can exhibit relatively promiscuous (e.g. p160s, RIP140 (1,2)) or highly 
17 
18 
19 
20 
21 
22 
23 We have investigated the molecular basis of interactions between the orphan 
24 
25 receptor COUP-TFII and the Krüppel zinc finger protein BCL11A (also known as CTIP1 and 
26 
27 Evi9) (7). BCL11A is a developmental regulator expressed in haematopoietic and neural 
28 
29 tissues whose overexpression is associated with acute leukaemia and B-cell lymphoma (8,9). 
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5 7 including retinal and neural development (22). BCL11A also shows high expression in the 
58 3 
59 
60 
Inactivating mutations in the BCL11A gene are associated with sickle cell disease and β-
thalassemias (10-12) and it was subsequently shown that BCL11A is a master regulator of 
foetal haemoglobin switching (13,14). This is due to its function as a corepressor through 
association with transcription factors such as COUP-TFII/NR2F2 (7), GATA1 and SOX6 (13), 
although the molecular basis of these interactions is not well understood. Moreover, BCL11A 
and its homolog BCL11B/CTIP2 may act in conjunction with other regulators such as BCL6 
(9), HP1α (15), SIRT1 (16), SUV39H1 (17), FOG1 (13) or the NuRD complex (18,19). 
The COUP-TF/NR2F subfamily of NRs has a wide range of functions in development, 
reproduction and homeostasis (20). Based on sequence homologies, they are closely 
related to the RXR/NR2B and HNF4/NR2A proteins, as well as the NR2E proteins 
TLX/NR2E1 and PNR/NR2E3 (20,21). COUP-TFII is widely expressed in mesenchymal 
tissues of the developing embryo and is essential for angiogenesis and organogenesis 
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interaction mapping studies. 
1 
2 
3 developing and adult brain (7,23,24). Previous work from Leid and colleagues revealed that 
4 
5 BCL11A and its homolog BCL11B are both capable of direct binding to COUP-TFII and that 
6 
7 these proteins are present in high molecular weight corepressor complexes in 
8 
9 neuroblastoma cells and other cell types (18,25). To understand the molecular basis of 
10 
11 BCL11A/COUP-TFII functional interactions in more detail, we therefore set out to 
12 
13 characterise the sequences that facilitate the formation of this complex using protein-protein 
14 
15 
16 
17 
18 
19 
20 MATERIALS & METHODS 
21 
22 Plasmid constructs 
23 
24 Mammalian cell expression plasmids pcDNA3.1 FLAG-BCL11AXL, pcDNA3.1 HA-
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
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44 
45 
46 
47 
48 
49 
50 
51 
52 
5 3 325), (594-707), (594-687), (594-670), (611-641), (651-707), (651-687) and (651-670)], 
54 
5 5 LexA-NSD1-(790-818) and LexA-COUP-TFII-LBD-(144-414) were generated by PCR 
56 
5 7 subcloning, or by ligation of phosphorylated, annealed oligonucleotide pairs into the 
58 4 
59 
60 
TLX and pcDNA3.1 HA-PNR-(89-410) were constructed by cloning modified PCR fragments 
into the pcDNA3.1 vector. The FLAG-BCL11A-XL L319A/Y656A/W659A, L318A and 
Y656A/W659A and GFP-BCL11A-XL L319A/Y656A/W659A constructs were generated by 
site-directed mutagenesis. Plasmids pCH110-lacZ (26), pRARβ2-Luc (27) and pTL1-COUP-
TFII (28) were gifts from E. Kalkhoven, G.Folkers and M. Leid, respectively. Full-length 
cDNA for BCL11A-XL and a GFP-BCL11A-XL construct were provided by M.J.S. Dyer (U. 
Leicester). 
For yeast two-hybrid expression, PCR fragments encoding the required sequences 
were subcloned in-frame into plasmids pBTM116mod and pASV3mod to generate LexA 
DNA binding domain (DBD) and VP16 acidic activation domain (AAD) fusion constructs, 
respectively. Construction of the LexA-SRC1-NID-(431-761) expression vector has been 
described previously (29). LexA–BCL11A-[(212-290), (212-295), (212-313), (212-329), (212-
376), (283-290), (295-376), (313-376), (326-376), (283-329), (302-325), (306-225), (310-
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1 
2 
3 pBTM116mod vector. Site-directed mutagenesis was used to introduce substitution 
4 
5 mutations into constructs LexA-BCL11A-(302-325), LexA-BCL11A-(310-325), LexA-
6 
7 BCL11A-(651-670) and LexA-NSD1-(790-818). These include mutations in RID1 (F315A; 
8 
9 S316A; R317A; L319A; R320A; L322A), RID2 (V655A; Y656A; S657A; Q658A; W659A; 
10 
11 L660A; G662A; Y663A) and NSD1 NR interaction domain (Y801A; K802A; F803A; S804A; 
12 
13 L806A; L807A; M808A; M809A; L810A; K811A; D812A). The following AAD-fusion 
14 
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25 
26 
27 
28 
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34 
35 
3 6 LBD-(200-462), TRβ-LBD-(169-456) and PPARγ-LBD-(173-475)] were described previously 
37 
3 8 (29). NSD1 template cDNA was a gift from F. Cammas & R. Losson. 
39 
4 0 GST-COUP-TFI-(1-467), GST-COUP-TFII-(144-414), GST-PNR-(89-410) and GST-
41 
42 TLX-(100-385) were constructed from by PCR subcloning into pGEX-DMH, a modified 
43 
44 version of pGEX-2TK vector (30). The construct pGEX-2TK-GST-PPARγ-LBD-(173-475) (31) 
45 
46 was a gift from E. Kalkhoven. 
47 
48 All constructs generated by PCR were sequenced to confirm their validity. The 
49 
50 expression of fusion proteins in yeast was monitored by Western blotting (See Supplemental 
51 
52 Fig.S1&S2) using antibodies recognising VP16 AAD (Santa Cruz SC7545) or LexA DBD 
53 
54 (Millipore 06-719) as described previously (1). 
55 
56 
57 
58 5 
59 
60 
constructs were generated by subcloning PCR fragments into the pASVmod vector; VDR-
LBD-(123-426), DAX-1-(1-140), SHP-(106-461), Rev-erb(3-LBD-(187-408), RORa-LBD-(106-
469), ROR(3-LBD-(98-459), H N F 4 Y - L B D - ( 8 8 - 4 0 8 ) , TR2-LBD-(195-467), TR4-LBD-(218-530), 
TLX-LBD-(100-385), PNR-LBD-(131-410), COUP-TFI-LBD-(151-467), COUP-TFII-LBD-
(144-414), EAR2-LBD-(121-399), ERRa-LBD-(169-423), Nur77-(1-599), NURR1-(1-598), 
LRH-1-LBD-(133-495) and GCNF-LBD-(138-475). AAD-COUP-TFII-LBD C-terminal 
deletions A12-(144-392), A11 -(144-380) and A10-(144-359) or substitution mutations 
(F221 A; V224A; R228A; I238A; V242A; R246A) were generated by PCR and site-directed 
mutagenesis. For PCR templates, NR cDNA vectors were purchased from Open Biosystems. 
Constructs AAD-[ERa-LBD-(282-595), AR-LBD-(626-919), RARa-LBD-(200-462), RXRa-
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appropriate supplements) in the presence of 10-6 M cognate ligand or vehicle. Preparation of 
cell-free extracts was by the glass bead method and (3-galactosidase assays were 
performed as described (1). Reporter (3-galactosidase activities in the presence or absence 
of ligand were determined for three individual transformants for each condition, in replicated 
experiments as stated. Ligands for RARa (all-trans retinoic acid), RXRa (9-cis retinoic acid), 
ERa (17-p- estradiol), AR (mibolerone), PPARy (roziglitazone), TRp (Triiodothyronine) and 
1 
2 
3 Yeast two-hybrid interaction assays 
4 
5 Saccharomyces cerevisiae L40 (trp1, leu2, his3, ade2, LYS2::(lexAop)4×-HIS3, 
6 
7 URA3::(LexAop)8×-LacZ) was co-transformed with LexA-fusion and AAD-NR-fusion 
8 
9 expression vectors using the lithium acetate method as described (1). Single transformants 
10 
11 containing the desired plasmids were selected on appropriate media and grown to late log 
12 
13 phase in 15 ml of selective medium (yeast nitrogen base containing 2% w/v glucose and 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
2 8 VDR (cholecalciferol) were purchased from Sigma. 
29 
30 
31 
32 
33 GST pull-down assays 
34 
35 GST fusion proteins were expressed in Escherichia coli BL21 using isopropyl-β-D-
36 
37 thiogalactopyranoside induction, and purified on glutathione-Sepharose beads (Amersham 
38 
39 Biosciences). The pcDNA3.1 BCL11AXL and associated mutant expression vectors were in 
40 
41 vitro transcribed/translated in the presence of [35S]-methionine in reticulocyte lysate 
42 
43 (Promega) according to the manufacturer’s instructions. Equalised amounts of GST proteins 
44 
45 were incubated with 35S-radiolabelled protein in NETN buffer (20 mM Tris, pH 8.0, 100 mM 
46 
47 NaCl, 1 mM EDTA, 0.5% NP-40) containing 1x complete protease inhibitors (Roche 
48 
49 Molecular Biochemicals) in the presence or absence of 10-6 M cognate ligand as described 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
previously (32). Samples were washed three times, and bound proteins were separated by 
SDS-PAGE. Radiolabelled proteins in dried gels were visualised by autoradiography. 
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plasmid (500 ng/well), pRARβ2-Luc (100 ng) luciferase reporter plasmid, and varying 
amounts of pTL1-COUP-TFII, pcDNA3.1 HA-TLX, pcDNA3.1-FLAG-BCL11A-XL or FLAG-
BCL11A-XL L319A/Y656A/W659A as indicated. Empty pcDNA3.1 expression vector was 
used to standardize the amount of transfected DNA. After 16 hours, fresh medium containing 
either 10-6 M all trans-retinoic acid ligand (ATRA) or vehicle was added. After a further 24 
hours, cells were harvested and cell-free extracts were prepared and assayed for luciferase 
activity using the Dual light® Luciferase Assay System (Applied Biosystems) and normalised 
to β-galactosidase activities. Reporter assays were performed in triplicate. 
1 
2 
3 Cell culture, transient transfections, reporter assays 
4 
5 U2OS and HEK293 cells were cultured in DMEM supplemented with 10% foetal bovine 
6 
7 serum (FBS) and maintained as described previously (30). Twenty four hours prior to 
8 
9 transfection, cells were replated in phenol red-free DMEM supplemented with 5% dextran 
10 
11 charcoal-stripped FBS. Transient transfections were performed using calcium phosphate co-
12 
13 precipitation. For reporter assays, transfected DNA included pCH110-lacZ internal control 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
3 3 Immunoprecipitation and Western Blots 
34 
3 5 For co-immunoprecipitation of recombinant proteins, HEK293 cells were co-transfected with 
36 
3 7 pTL1-COUP-TFII, pcDNA3.1 HA-TLX or pcDNA3.1 HA-PNR-(89-410) in combination with 
38 
39 pcDNA3.1 FLAG-BCL11A-XL or mutants. At 48 hours post-transfection, the cells were 
40 
41 washed in PBS, harvested and nuclear extracts prepared (2mg) in 500 µl with Triton X-100 
42 
43 lysis buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 1 % Triton X-100, 1 mM PMSF, 1mM DTT, 
44 
45 and 1x protease inhibitor cocktail). Lysates were equalised for protein content, pre-cleared 
46 
47 by incubation with protein-G Plus Agarose (Santa-Cruz) and FLAG-tagged proteins were 
48 
49 immunoprecipitated using 1 µg of anti-FLAGM2 (A2220, Sigma) and 20 µl Protein-G 
50 
51 agarose overnight with gentle agitation. Agarose beads were then washed 5 times in ice cold 
52 
53 PBS and precipitated proteins resolved by SDS-PAGE and detected by Western blotting 
54 
55 
56 
57 
58 7 
59 
60 
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1 
2 
3 using anti-BCL11A (14B5, Santa Cruz), anti-COUP-TFII (H7147, Abcam), anti-TLX (S-23, 
4 
5 Santa Cruz or anti-HA (F-7, Santa Cruz) as appropriate. 
6 
7 To assess co- immunoprecipation of endogenous proteins, dissected brain regions 
8 
9 from wild type mice were snap frozen on dry ice and homogenised in Triton-X100 lysis buffer 
10 
11 (50 mM Tris-HCl pH8, 150 mM NaCl, 1 % Triton X-100, 1 mM PMSF, 1mM DTT, 1x protease 
12 
13 inhibitors), sonicated and cleared by centrifugation. Equalised amounts of protein were 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
3 6 was used at a dilution of 1:50 and detected using DAB (brown) staining. Sections were 
37 
3 8 counterstained with haematoxylin (blue). Tissue extractions were performed in accordance 
39 
4 0 with local and national rules under the Animals (Scientific Procedures) Act UK 1986. 
41 
42 
43 
44 Electrophoretic Mobility Shift Assay (EMSA) 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
immunoprecipitated with the appropriate antibody as described above. The precipitates were 
resolved by SDS-PAGE for Western blot analysis. 
Immunohistochemistry 
A 3 month old male C57BL/6J mouse was anaesthetised and sacrificed by transcardial 
perfusion with 4% paraformaldehyde in PBS. The brain was removed and immersion fixed in 
the fixative for 24 h at 4°C. Coronal tissue sections were prepared after embedding in 
paraffin. Immunohistochemical staining was performed using a Dako Envision kit following 
manufacturer’s instructions, and incorporating a microwave antigen retrieval step [10 
minutes in 10mM sodium citrate (pH 6.0)]. Primary antibody α-BCL11A (14B5, Santa Cruz) 
Forward and reverse strands of nucleic acid probes were subjected to 5’-hydroxyl 
end labelling with [γ32P]-ATP using T4 polynucleotide kinase. The labelled probes were 
annealed and purified on G-25 sephadex columns, before being adjusted to 100,000 cpm/µl 
for use in binding assays. Sequences of the probes used in this study are listed in 
Supplemental Fig. S3A. Nuclear extracts (NE) were prepared from HEK293 cells transfected 
with pTL1-COUP-TFII, pcDNA3.1 HA-TLX, pcDNA3.1 FLAG-BCL11A-XL or pcDNA3.1 
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binding mixes to validate the identity of protein/DNA complexes. Binding mixes were loaded 
onto 5% polyacrylamide gels and electrophoresed in 0.5x TBE prior to being visualised by 
autoradiography. 
1 
2 
3 (Mock). Expression of the recombinant proteins were verified by western blots (Fig. S4B). 
4 
5 Indicated amounts of NE were incubated with 1 µl nucleic acid probe, 1µg poly(dI:dC)·(dI:dC) 
6 
7 and 3µg bovine serum albumin in EMSA buffer (20 mM HEPES-KOH pH 7.9, 12 % v/v 
8 
9 glycerol, 50 mM KCl, 1 mM DTT) to a final volume of 10 µl. Binding mixes were incubated at 
10 
11 room temperature for 20 min to allow DNA/protein complex formation. Where appropriate, 
12 
13 specific antibodies for FLAG (A2220, Sigma), or COUP-TFII (H7147, Abcam) were added to 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 Chromatin Immunoprecipitation 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
5 3 with 10µg of specific antibody for COUP-TFII (Active motif, 61213) or BCL11A (Abcam, 
54 
55 19489) overnight at 4°C. The beads were washed (x3) for 10 min in 1xPBS-Tween and the 
56 
57 immunoprecipitate was eluted in 60µl elution buffer (0.2M glycine pH 2.5). Samples were 
58 9 
59 
60 
Chromatin was prepared from DOHH2 or K562 cells grown in RPMI supplemented with 
foetal bovine serum. Approximately 1.5x107 cells per condition were fixed with 1 % 
formaldehyde for 8 min at room temperature and subsequently quenched with 0.125M 
glycine. Cells were washed (x3) in ice-cold PBS, resuspended in cell lysis buffer (5 mM Tris-
Cl (pH 8.0), 85 mM KCl, 0.5% NP-40) and incubated for 10 min on ice. Samples were then 
harvested at 1000 rpm for 10 min at 4 °C and the supernatant aspirated. Chromatin was 
extracted from the nuclear pellet by resuspension in nuclei lysis buffer (50 mM Tris-Cl (pH 
8.0), 10 mM EDTA, 1 % SDS) supplemented with EDTA-free protease inhibitors (Roche) for 
10 min on ice. Chromatin was sonicated using a Diagenode water bath sonicator under 
conditions optimised to give a DNA fragment length of 200-500 bp. DNA content was 
measured using a bioanalyser (Agilent) and fragment size verified by gel analysis. 
Immunoprecipitation was performed with PureProteome magnetic beads (Millipore) as per 
manufacturer’s protocol. 10-25µg of chromatin was used for each IP which was incubated 
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quantitative real-time polymerase chain reaction (qPCR) reaction as described previously 
(33). qPCR reactions were done in triplicate, and the samples were analyzed on a 2% 
agarose gel to verify that PCR products were of the expected size. Primers were designed to 
amplify regions selected by bioinformatic analysis, to detect recruitment of factors at the 
human beta-globin locus. Primer sequences are listed in Supplemental Figure S3B. 
RT-qPCR 
K562 cells were maintained in RPMI supplemented with 10% foetal calf serum (FCS) and 2 
mM glutamine at 37°C in 5% CO2. Approximately 2.5x105 cells were transfected with 1µg of 
1 
2 
3 then neutralized with 1M Tris (pH 8.5), reverse-crosslinked by incubating at 65°C overnight 
4 
5 and treated with protease K. DNA was purified through Macherey-Nagel PCR purification kit 
6 
7 according to manufacturer’s protocol. 1µl of ChIP-enriched DNA was used in a 20µl 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
2 8 GFP, GFP-BCL11AXL or GFP-BCL11AXL (L319A/Y656A/W659A) using the Neon 
29 
3 0 electroporation transfection system (Invitrogen) with the following parameters, 1350v 10ms, 
31 
32 4 pulses. At 48 hours post transfection, Bgl3 and γ-globin gene transcripts were measured 
33 
34 by RT-qPCR, which was carried out as described previously (33) using primers as described 
35 
36 in Supplemental Figure S3C. GAPDH transcript levels were used as the reference gene and 
37 
38 assays were performed in triplicate. 
39 
40 
41 
42 RESULTS 
43 
44 F/YSXXLXXL/Y motifs mediate interaction of BCL11A with COUP-TFII LBD 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 10 
59 
60 
BCL11A has been previously reported to contain two distinct regions (264-378 and 602-776) 
that can bind COUP-TFII proteins (7). To identify the interacting sequences more precisely, 
yeast two-hybrid (Y2H) mapping experiments were performed. Expression data for all two-
hybrid constructs and confirmation of the lack of intrinsic reporter activation activities is 
provided in Supplemental Figures S1 & S2. Consistent with the previous report, the BCL11A 
sequences 212-376 and 594-707 were both capable of binding to the COUP-TFII LBD (144-
Page 11 of 42 Nucleic Acids Research 
1 
2 
3 414) independently of any added ligand (Fig. 1A). Extensive deletion mapping precisely 
4 
5 identified two short sequences (310-325 and 651-670; termed here RID1 and RID2) that 
6 
7 were sufficient to bind the COUP-TFII LBD (Fig 1A). 
8 
9 To identify residues within RID1 and RID2 that are required for COUP-TFII LBD 
10 
11 binding, alanine scan mutagenesis was performed. As show in Fig.1B, the substitutions 
12 
13 F315A, S316A, L319A or L322A abrogated the binding of RID1 to COUP-TFII LBD. In 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
3 6 the LXXLL (1) and CoRNR box motifs (3). Thus, we conclude that a core α-helical sequence 
37 
38 motif fitting the consensus [F/Y]SXXLXX[L/Y] is important in mediating the interaction of 
39 
40 BCL11A with the COUP-TFII nuclear receptor. 
41 
42 To confirm that RID1 and RID2 are both necessary and sufficient for the interaction 
43 
44 of BCL11A with COUP-TFII, we introduced substitution mutations (L319A/Y656A/W659A) in 
45 
46 full-length FLAG-BCL11A-XL that were predicted to prevent COUP-TFII binding based on 
47 
48 the yeast two hybrid data. We then tested the effect of these mutations on the interaction of 
49 
50 in vitro translated, isotopically-labelled full-length BCL11A-XL proteins with GST fusion 
51 
52 proteins containing the LBDs of COUP-TFI/NR2F1 and COUP-TFII/NR2F2. We also 
53 
5 4
 included GST- LBD proteins consisting of the LBDs of TLX/NR2E1 and PNR/NR2E3, which 
55 
5 6
 are the close relatives of the NR2F subfamily, and PPARγ/NR1C3 whose sequence is more 
57 
58 11 
59 
60 
contrast R317A and R320A retained substantial COUP-TFII binding, albeit that the reporter 
activity was 5-fold lower, indicating these residues are less critical for complex formation. 
Thus, the core sequence FSXXLXXL appears to be essential for binding of the RID1 
sequence to COUP-TFII LBD. Similarly, V655A, Y656A, S657A, W659A, L660A and Y663A 
substitutions in RID2 prevented its interaction with COUP-TFII LBD whereas Q658A and 
G662A had no deleterious effect on binding in yeast two-hybrid assays (Fig. 1B). This 
indicates that the sequence motif VYSXWLXXY is required for the interaction of RID2 with 
COUP-TFII. Both RID1 and RID2 are well conserved in BCL11A homologs across species 
(Fig. 1C), and also within the closely related BCL11B gene (Fig. 4A), and are predicted by 
the PSIPRED (http://bioinf.cs.ucl.ac.uk) algorithm to form amphipathic α-helices similar to 
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was detected with controls i.e. GST alone, or GST- PPARγ LBD in the presence or absence 
of the agonist roziglitazone (Fig. 1D). These results suggested that BCL11A-XL may 
undergo selective interactions with different members of the NR family, and that the RID1 
and RID2 sequences are required for this function. 
To assess the role of RID1 and RID2 sequences in promoting gene repression by 
COUP-TFII/BCL11A-XL complexes, reporter assays were performed using a RARβ2 
1 
2 
3 divergent. As shown in Fig. 1D, interactions were detected between wild type BCL11A-XL 
4 
5 and GST-COUP-TFI, GST-COUP-TFII, GST-TLX and GST-PNR proteins, suggesting 
6 
7 BCL11A-XL binds directly to these LBDs. In contrast, the double mutant (mRID1/2) failed to 
8 
9 bind to NR2E/F LBDs under similar conditions. No interaction of the wild type BCL11A-XL 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
2 4 promoter reporter. The RARβ2 gene proximal promoter contains binding sites for both RARs 
25 
2 6 and COUP-TFs, which have been shown to cooperate to activate expression of this gene in 
27 
28 response to all trans retinoic acid (ATRA) treatment (34). We confirmed that COUP-TFII can 
29 
30 associate with the RARβ2 proximal promoter sequences containing the COUP-TFII binding 
31 
32 site in EMSA assays (Supplemental Fig.S4A). Consistent with this, the RARβ2 reporter was 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
4 7 motifs appears to be important for its corepressor function on the RARβ2 promoter. TLX has 
48 
49 also been reported to activate the RARβ2 promoter in response to ATRA (35). Reporter 
50 
51 assays confirmed that TLX-mediated activation of the RARβ2 reporter gene in response to 
52 
53 
54 
55 
56 
57 
58 12 
59 
60 
induced by ATRA treatment due to the action of endogenous RARs, and was further 
activated by ectopic expression of COUP-TFII (Fig. 1E). However, co-expression of COUP-
TFII with wild type BCL11A-XL protein repressed RARβ2 reporter activity. The repressive 
effect of BCL11A-XL on the RARβ2 reporter was inhibited by disruption of both RID1 and 
RID2 motifs, whereas only partial rescue was achieved by disruption of RID1 or RID2 alone 
(Fig. 1F). Thus, physical interaction of BCL11A-XL with COUP-TFII via RID1 and RID2 
ATRA is repressed by BCL11A-XL to a similar extent as that observed for COUP-TFII (Fig. 
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and Bgl3 genes 
To support the above conclusions, we assessed whether the RID1 and RID2 motifs 
are important for regulation of endogenous genes that are reported to be targets of COUP-
TFII and BCL11A. Developmental regulation of the mammalian β-globin-like locus in 
erythroid cells is achieved as a consequence of functional interactions of BCL11A with 
transcription factors such as GATA factors, COUP-TFII, Sox6, and NF-Y (13,14,36,37). The 
switch from foetal to adult globin gene expression requires BCL11A, which acts to repress 
1 
2 
3 1G). Thus, the ability of by NR2E/Fs to recruit BCL11A appears to be important for their 
4 
5 transcription regulatory functions. 
6 
7 
8 
9 RID1 and RID2 motifs are required for BCL11A-mediated repression of human γ-globin 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
2 6 the foetal-specific γ-globin genes (Aγ and Gγ) (13,36,38-40). Similarly, COUP-TFII has been 
27 
28 shown to repress γ-globin gene expression (37,41-43). BCL11A was also reported to repress 
29 
30 the expression of the Bgl3 (AY034471) sequence, a series of non-coding transcripts located 
31 
32 within the globin γδ-intergenic region (Fig. 2A), which is co-regulated with the γ-globin genes 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
5 3 expression, very high levels of γ-globin and Bgl3 transcripts were detected in K562 cells 
54 
55 using RT qPCR (Fig. 2B). By contrast, γ-globin and Bgl3 transcripts were detected at 
56 
57 
58 13 
59 
60 
(38). We therefore set out to find evidence for co-recruitment of COUPTF-II and BCL11A to 
regulatory sites in the globin locus, and to assess whether disruption of BCL11A/COUP-TFII 
complexes would impact on transcription of γ-globin and Bgl3. 
In order to select a suitable cell line model, we assessed a number of leukaemia and 
lymphoma cell lines for expression of BCL11A-XL protein. Western blots indicated that 
BCL11A-XL is robustly expressed in the B-cell lymphoma DOHH2 cells and U937 myeloid 
leukaemia cells, whereas expression levels are very low in the erythroleukaemia cell line 
K562 and the promyelocytic leukaemia HL60 cell line (Supplemental Fig.S5) (13,37,40). 
Consistent with current models that BCL11A functions as a repressor of foetal globin gene 
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1 
2 
3 extremely low levels (by several orders of magnitude) in the DOHH2 cell line (Fig. 2B), which 
4 
5 expresses relatively high levels of BCL11A-XL protein. 
6 
7 We next examined the association of BCL11A and COUPTFII proteins with key 
8 
9 regulatory sites within the globin locus (depicted schematically in Figure 2A). Chromatin IP 
10 
11 experiments confirmed that BCL11A protein was detected at DNAse hypersensitive site 3 
12 
13 (HS3) within the locus control region (LCR) in DOHH2 cells, but not in chromatin prepared 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
4 4 binding to these sequences in the EMSA assays (Fig. 2G). In contrast to COUP-TFII, 
45 
4 6 BCL11A did not produce strong shifts of EMSA probes, although at higher concentrations of 
47 
4 8 BCL11A rather diffuse mobility shifts of Bgl3 probes were observed (Supplemental Fig. S6A). 
49 
50 Although the mobility of the specific COUP-TFII/DNA complexes was altered by BCL11A, 
51 
52 suggesting potential interaction of COUP-TFII and BCL11A in vitro we did not observe stable 
53 
54 COUP-TFII/ BCL11A/DNA complexes using this assay (Supplemental Fig. S6A&B). Similarly 
55 
56 weak binding of BCL11A proteins to the gamma globin promoter sequence in EMSA assays 
57 
58 14 
59 
60 
from K562 cells (Fig. 2C). Moreover, ChIP experiments using DOHH2-derived chromatin 
confirmed the presence of both BCL11A and COUP-TFII at the HS2 and HS3 sites of the 
LCR, the globin promoter region, the Bgl3 region, but not at the DNAse hypersensitive site 3’ 
to the locus (HS1-3’) (Fig. 2D). In contrast, we did not detect BCL11A-XL at these sites in 
chromatin prepared from K562 cells, under similar experimental conditions (data not shown). 
These data are consistent with the potential presence of BCL11A/COUP-TFII complexes at 
key regulatory sites within the globin locus, and provide the first evidence that COUP-TFII 
may be involved in regulating the expression of the putative lncRNA Bgl3. 
Analysis of the Bgl3 sequence for potential NR binding motifs highlighted two distinct 
regions containing consensus AGGTCA half sites, which were confirmed as COUP-TFII 
binding sites in EMSA assays (Fig. 2E). Mutation of these half-sites disrupted the formation 
of COUP-TFII/DNA complexes (Fig.2E), while the presence of COUP-TFII in the complexes 
was confirmed by antibody supershifts (Fig. 2F). These binding sites in Bgl3 appeared to be 
specific for COUP-TFII, as neither TLX/ NR2E1 nor PNR/NR2E3 were capable of strong 
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expression, GFP-tagged versions of wild type BCL11A-XL or the RID1/2 mutant were 
ectopically expressed in K562 cells. The wild type GFP-BCL11A was able to repress 
expression of the endogenous Bgl3 and γ-globin genes (Fig. 2H). In contrast, expression of 
the GFP-BCL11A-XL RID1/2 mutant in K562 cells resulted in a significantly enhanced 
expression of γ-globin over control (Fig. 2H), suggesting a dominant negative effect such as 
1 
2 
3 has been reported (37).Nonetheless, our results are consistent with reports that BCL11A can 
4 
5 be recruited to the Bgl3 locus, and further suggest a role for COUP-TFII/BCL11A complexes 
6 
7 in regulating the Bgl3 transcription. 
8 
9 To assess the effect of RID1/2 mutations on the expression of Bgl3 and y-globin 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 sequestration of other co-repressors. Taken together our results indicate that repression of 
23 
24 endogenous y-globin and Bgl3 genes by BCL11A is dependent on the functionality of the 
25 
26 RID1 and RID2 motifs, and thus provides strong evidence for a role for COUP-TFII in 
27 
28 regulating expression of the Bgl3 locus. 
29 
30 
31 
32 BCL11A RID1 and RID2 motifs are highly selective for the NR2E/F subfamily 
33 
34 To determine whether the RID1 and RID2 sequences mediate binding to other NRs 
35 
36 we assessed interactions of LexA-RID1 and LexA-RID2 with a panel of 25 different VP16 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 interactions were observed with the orphan receptors NR1 F1/RORa, NR1F2/RORP, 
54 
55 NR2A2/HNF4y, NR3B1/ERRa, NR5A2/LRH1 and NR6A1/GCNF (Fig. 3A). Similar 
56 
57 
58 15 
59 
60 
AAD-NR LBD fusions in Y2H assays. The nuclear receptor interaction domain (NID) of the 
human SRC1 (489-827), containing three LXXLL motifs that mediate binding to liganded NR 
LBDs (1), was used for comparison. Cognate ligands (1 |JM) were added to yeast 
transformants cultured overnight prior to preparation of cell-free extracts for reporter assays. 
As shown in Fig. 3A, the SRC1 NID displayed strong ligand-stimulated interactions with 
NR1A2/TRP, NR1B1/RARa, NR1C3/PPARy, NR1I1/VDR, NR2B1/RXRa, NR3A1/ERaand 
NR3C4/AR, as we have previously reported (29,44). In addition, strong ligand-independent 
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1 
2 
3 observations of SRC1 NID binding to these NR LBDs have been reported in the literature or 
4 
5 protein interaction databases (e.g. BioGRID), with the exception of GCNF LBD which, to our 
6 
7 knowledge, was not previously reported to bind SRC1. We did not detect significant 
8 
9 interactions of the SRC1 NID with NR0B1/DAX-1, NR0B2/SHP, NR1D1/Rev-erbβ, 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
3 6 co-immunoprecipitation experiments. HEK293 cells were transiently transfected with 
37 
3 8 expression vectors for FLAG-BCL11A wild type protein, RID1 mutant (L319A), RID2 mutant 
39 
4 0 (Y656A/W659A) or a RID1/2 double mutant (L319A/Y656A/W659A) in combination with 
41 
42 haemagglutinin (HA)-tagged TLX or PNR, or untagged COUP-TFII proteins. Co-
43 
44 immunoprecipitation experiments confirmed that wild type BCL11A-XL was able to form 
45 
46 complexes with COUP-TFII, TLX and PNR in HEK293 cells (Fig. 3B) confirming the yeast 
47 
48 two hybrid results. Moreover, interactions with all three NRs were abrogated or reduced by 
49 
50 the double RID1/RID2 mutation (Fig. 3B), confirming the contribution of these motifs to 
51 
52 establishing the observed interactions. The loss of either RID1 or RID2 reduced the ability of 
53 
54 BCL11A-XL to bind COUP-TFII, suggesting both motifs may be required to form bivalent 
55 
56 contacts with homodimer or heterodimer complexes of COUP-TFII. TLX on the other hand 
57 
58 16 
59 
60 
NR2C1/TR2, NR2C2/TR4, NR2E1/TLX, NR2E3/PNR, NR2F1/COUP-TFI, NR2F2/COUP-
TFII, NR2F6/EAR2, NR4A1/Nurr77 or NR4A2/NURR1 under these conditions. In contrast, 
RID1 and RID2 sequences failed to bind any of the liganded receptor LBDs tested, or any 
orphan receptor LBD that showed an ability to interact with SRC1 (Fig. 3A, middle and right 
panels). However, RID1 displayed strong binding to the LBDs of NR2E1/TLX, NR2E3/PNR, 
NR2F1/COUP-TFI, NR2F2/COUP-TFII and NR2F6/EAR2. Similarly, RID2 showed strong 
binding to NR2E1/TLX, NR2F1/COUP-TFI, NR2F2/COUP-TFII and NR2F6/EAR2, but failed 
to interact with the photonuclear specific receptor NR2E3/PNR in these experiments. These 
results demonstrate a remarkable selectivity of BCL11A RID1 and RID2 motifs for the NR2E 
and NR2F subfamily of receptors. 
To confirm that the observed interactions of RID1 and RID2 with NR2E and NR2F 
proteins in yeast reflect interactions of full-length proteins in mammalian cells, we performed 
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1 
2 
3 was more sensitive to mutations in RID2, as RID1 mutation (L319A) alone had little effect on 
4 
5 its ability to form a complex with BCL11A-XL under these conditions. In contrast, mutation of 
6 
7 RID2 had no deleterious effect on PNR binding, suggesting that only RID1 is required for 
8 
9 interaction with this nuclear receptor, consistent with the yeast two hybrid data (Fig. 3A). 
10 
11 Thus, these data confirm that NR2E/F subfamily members make selective contacts with 
12 
13 BCL11A proteins through RID1/RID2 motifs, albeit with differing sensitivities to the ablation 
14 
1 5
 of either motif. 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
4 4 BCL11A in mouse hippocampus and cortex, with lower levels detected in the striatum and 
45 
4 6 very low levels in the cerebellum (Fig. 3D). In contrast, TLX protein was detected in all four 
47 
4 8 of these regions (Fig. 3D). Importantly, immuno-precipitation of BCL11A proteins from cortex 
49 
50 revealed co-precipitation of TLX but not the β-actin control (Fig. 3E), confirming the 
51 
52 existence of endogenous complexes of TLX and BCL11A in vivo. We also attempted to 
53 
54 detect PNR/BCL11A complexes in whole eye homogenates from adult mice. However, 
55 
56 although PNR was readily immuno-precipitated from these extracts, we were unable to 
57 
58 17 
59 
60 
TLX is an important regulator of stem cell fate in forebrain and retina (45), and 
defects in its expression are associated with behavioural abnormalities, blindness and 
glioblastoma as reviewed in (46). In addition to its role in development, TLX expression has 
been detected in neural stem cells in adult brain within cells lining the subventricular zone, 
and the subgranular layer of the dentate gyrus, as well as in striatum and cortex (47). PNR 
expression in the adult is restricted to the photoreceptor cell layer of the retina (48). Previous 
studies have reported the detection of the BCL11A transcripts in both developing and adult 
murine brain (24). To examine BCL11A protein expression in brain, we performed 
immunohistochemical staining on mouse brain tissue sections using an antibody that detects 
both the L and XL isoforms. Strong expression of BCL11A was detected in cortical regions 
and also in pyramidal cell layers in the CA1 and CA3 regions of the hippocampus. BCL11A 
protein is localised to the nucleus in these cells, e.g. as shown for the pyramidal layer of the 
hippocampus (Fig. 3C). Western blots on tissue homogenates confirmed the expression of 
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Helix 3 (F221, V224, R228) and Helix 5 (I238, V242, R246) are likely to be positioned to 
come in contact with α-helices in docking cofactors (Fig.4A). We therefore generated AAD-
COUP-TFII LBD substitution mutants for Y2H assays. As shown in Fig. 4B, substitution of 
F221 with alanine completely abrogated the binding of both RID1 and RID2, indicating that 
this residue is essential for binding to the F/YSXXLXXL/Y helices. The ability of the F221A 
mutant to form homodimers with wild type COUP-TFII LBD was not affected, showing that 
this mutation is unlikely to perturb the overall structure of the domain (Fig. 4B). While the 
V224A mutant appeared unable to bind RID2, RID1 binding appeared unaffected (Fig. 4B). 
However, western blots indicated that this mutant was expressed at a 2-fold lower level than 
1 
2 
3 detect expression of BCL11A in the eye (data not shown), suggesting that PNR/BCL11A 
4 
5 interactions may occur only during embryo development. 
6 
7 
8 RID Interaction requires the F221 Residue in Helix 3 of the COUP-TFII LBD 
9 
10 We noted from the structure of the COUP-TFII LBD (PDB:3CJW) that residues in 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
3 1 other constructs in this series (Supplementary Fig. S2C). Consistent with this, the V224A 
32 
3 3 also showed reduced reporter activation due to homodimer formation (by about 2.5 fold), 
34 
3 5 which we attribute to its slightly reduced expression level. Mutated LBDs with replacements 
36 
3 7 of I238, V242 or R246 in Helix 5 (or K362 in Helix 10, data not shown) retained substantial 
38 
39 ability to bind RID1 or RID2, albeit that binding of RID1 by the R246A mutant was reduced. 
40 
41 This suggests that these residues are not essential for binding of COUP-TFII LBD to 
42 
43 BCL11A. Substitution of R228, which is the equivalent of the conserved lysine in the charge 
44 
45 clamp contacting LXXLL motifs in liganded NRs, did not disrupt the interaction of the COUP-
46 
47 TFII LBD with RID1 or RID2. Indeed, reporter activation due to interaction of the R228A 
48 
49 mutant with RID1 was enhanced in comparison to the wild type LBD (Fig. 4B). As R228 is 
50 
51 predicted to stabilise the orientation of H12 within the cofactor docking site (49), it is possible 
52 
53 that disruption of this salt bridge might facilitate H12 displacement by cofactors. We 
54 
55 conclude from these experiments that Helix 3 is likely to form part of the RID1 and RID2 
56 
57 
58 18 
59 
60 
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structure (49) thus facilitating its interaction with cofactors. We did not observe any effect of 
ATRA on the binding of coactivator or corepressor peptides in two hybrid assays, or on 
interactions of full-length proteins in vitro (data not shown), although we cannot rule out the 
presence of low levels of endogenous ATRA in these assays. However, deletion of the 
COUP-TFII AF2 helix ( 393-414) resulted in a complete loss of interaction with RID1 and 
RID2, and a failure to form heterodimers with full-length LBD (Supplementary Fig.S2D), 
suggesting that the AF2 helix is required to stabilise the COUP-TFII LBD structure. 
1 
2 
3 docking site on the COUP-TFII LBD surface. While F221 appears critical for binding RID1 
4 
5 and RID2, whereas V224 may be essential for RID2 binding only. This is suggestive of 
6 
7 subtle differences in how the two motifs contact COUP-TFII. 
8 
9 In the ‘auto-inhibited’ structure of the COUP-TFII LBD, the activation function-2 (AF2) 
10 
11 helix occupies the cofactor binding groove on the LBD surface (Fig. 4A). It has been 
12 
13 postulated that binding of COUP-TFII to retinoic acid (ATRA) ligand would alter the LBD 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
3 1 Differential requirements of COUP-TFs, TLX and PNR for RID1 and RID2 sequences 
32 
3 3 To determine whether members of the NR2E/F subfamily make similar contacts with the 
34 
3 5 RID1 and RID2 motifs, yeast two-hybrid assays were performed to assess the interactions of 
36 
3 7 NR2E/F receptors with the mutant RID1 and RID2 constructs described in Fig. 1B. As shown 
38 
39 in Fig. 4C&D, COUP-TFI showed a similar pattern of interactions with RID1 and RID2 
40 
41 mutants as found for COUP-TFII (Fig. 1B), showing a requirement for FSXXLXXL in RID1 
42 
43 (Fig. 4C), and VYSXWLXXY in RID2 (Fig. 4D). The EAR2/NR2F6 LBD showed only two-fold 
44 
45 lower reporter activation due to interactions with F315A, suggesting this residue is less 
46 
47 critical for its recruitment of RID1 (Fig. 4C). Similarly, EAR2 engagement of RID2 was 
48 
49 somewhat different to COUP-TFI/II, as alanine substitution of Y656 or S657 had only a minor 
50 
51 effect on reporter activation. This suggests a requirement for VXXXWLXXY in RID2 to bind 
52 
53 EAR2. TLX binding to RID1 did not require S316A (Fig. 4C) and similarly S657 in RID2 was 
54 
55 dispensible for TLX recruitment (Fig. 4D). Combined with other interaction data, this 
56 
57 
58 19 
59 
60 
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1 
2 
3 suggests that TLX requires FXXXLXXL and YXXXLXXY in RID1 and RID2, respectively. 
4 
5 Interestingly, the SANT domain repressor proteins Atrophin-1 (ATN1) and RERE/ATN2, 
6 
7 which can bind TLX (50) and PNR (51), contain a motif termed the ATRO box motif that is 
8 
9 required for interaction with TLX (50), This sequence (LXXL) shows partial overlap with the 
10 
11 C-terminal portions of RID1 and RID2 (Fig. 5A). 
12 
13 The interaction of PNR with BCL11A was somewhat distinct from other members of 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
3 9 similarity searches revealed the existence of similar motifs in other transcriptional regulators 
40 
4 1 including the NR cofactor SOTOS overgrowth syndrome gene product NSD1 (Fig. 5A). 
42 
4 3 NSD1 is a SET domain lysine methyltransferase protein containing two regions that exhibit 
44 
4 5 differential interactions with NRs (52). The sequence 738-788 was reported to bind to the 
46 
47 LBD of RARα in the absence of ligand, whereas addition of ATRA disrupted this interaction 
48 
49 (52), similar to the binding behaviour of corepressors such as NCOR and SMRT with RARs 
50 
51 and other liganded NRs (3-5). In contrast, an adjacent region of the NSD1 sequence (termed 
52 
53 NID+L) displayed binding properties typical of a coactivator in that it bound to the LBDs of 
54 
55 
56 
57 
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the NR2E/F subfamily, in that it was found to be dependent on RID1, but much less so on 
the integrity of RID2. Similar to COUP-TFI/II and TLX, binding of PNR to RID1 required F315, 
L319 and L322. However, unlike other NRs, PNR was also sensitive to mutation of R317 
and R320 (Fig. 4C). This result indicates a requirement for the sequence FXRXLRXL to 
promote stable interaction of BCL11A with PNR. As the RID2 motif lacks equivalent arginine 
residues at these positions, this might account for the apparent preference of PNR for RID1. 
Conservation of F/YSXXLXXL/Y motifs in NSD1 and other proteins. 
We have shown here that BCL11A RID1 and RID2 sequences mediate selective 
interactions with the NR2E/F subfamily, and that F/YSXXLXXL/Y motifs are conserved in 
vertebrate, insect and arthropod orthologs of BCL11A/B proteins (Fig. 1C). Sequence 
RARα, RXRα, ERα and TRα, in a ligand-dependent manner. This function was mapped to a 
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NR1B1/RARa, NR2B1/RXRa and NR3A1/ERa as reported previously, but also with 
NR1C3/PPARy, NR1I1/VDR, NR1A2/TRP, and NR3C4/AR. Substantial constitutive 
interaction with RXRa and PPARy occurred in the absence of exogenous ligand for the 
reasons previously outlined, consistent with similar results for SRC1 and MED1 NIDs 
1 
2 
3 LXXLL-type sequence defined as the sequence NSD1 803-FXXLL-807 (52), which is 
4 
5 coincident with the RID1 -like sequence 803-FSXXLXXL-810 (Fig 5A). To test whether this 
6 
7 sequence would facilitate interactions with NR2E/F proteins, as predicted by our findings, we 
8 
9 performed two-hybrid assays. As shown in Fig. 5B, the construct LexA-NSD1 790-818, 
10 
11 which contains an RID1 -like motif, showed strong ligand-dependent interactions with 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 (1,29,44). In addition, as observed for SRC1 NID, strong constitutive interactions were 
23 
24 observed with the orphan receptors NR1 F1/RORa, NR1F2/RORP, NR2A2/HNF4y, 
25 
26 NR3B1/ERRa, NR5A2/LRH1 and NR6A1/GCNF, but not with NR0B1/Dax-1, NR0B2/SHP, 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 NR selectivity (1,29,44). In contrast to the BCL11A RID1, the NSD1 NR-binding sequence is 
56 
57 coincident with FXXLL and LXXML motifs, both of which are LXXLL variants that can 
58 21 
59 
60 
NR1D2/Reverbβ, NR2C1/TR2, NR2C2/TR4, NR4A1/Nurr77, NR4A2/NURR1 or 
NR2E3/PNR (Fig. 5B). However, unlike the SRC1 NID (Fig. 3A), the NSD1 NID+L containing 
construct also showed strong interactions with NR2F1/COUP-TFI, NR2F2/COUP-TFII, 
NR2F6/EAR2 and NR2E1/TLX (Fig. 5B). This result is consistent with the hypothesis that a 
FSXXLXXL sequence within NSD1 can mediate interactions with the NR2E/F subfamily. The 
failure of the NSD1 motif to interact with PNR LBD in these assays is also consistent with the 
observed differential sequence requirement of PNR e.g. for a FXRXLRXL sequence, as 
present in BCL11A proteins. 
Our data indicate that short alpha helical motifs present in cofactors determine 
differential NR-binding selectivity. Although BCL11A and NSD1 both have FSXXLXXL 
sequences, BCL11A is highly selective for NR2E/F subfamily, whereas NSD1 shows a much 
broader range of interactions. We hypothesised that this differential selectivity may be due to 
the sequence context, which we have previously shown to be important in determination of 
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1 
2 
3 potentially dock with ligand-dependent NRs. Thus we reasoned that the NSD1 motif may 
4 
5 contain structural features that are recognised by different NR subgroups. To test this we 
6 
7 undertook substitution mutagenesis of the NSD1 motifs to determine the effects on binding 
8 
9 of NRs from different binding classes. As shown in Fig. 5C, interaction of the NSD1 motif 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
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21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
3 6 for the NR2E/F subfamily, in contrast with LXXLL motifs found in coactivators such as SRC1 
37 
3 8 (Fig.3A) and MED1 (data not shown) which do not show strong binding to these NRs. Our 
39 
4 0 study also reports the interaction of TLX/NR2E1 and PNR/NR2E3 with the developmental 
41 
42 co-repressor BCL11A. 
43 
44 Interactions of BCL11A with COUP-TFII were known from previous studies, and 
45 
46 there is evidence that these proteins cooperate to regulate expression of genes in the globin 
47 
48 locus and are thus important in foetal to adult haemoglobin switching. Early studies 
49 
50 described mutations within the human γ-globin promoter that are associated with the 
51 
52 
53 
54 
55 
56 
57 
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with the LBD of TLX binding required a FSXLLXML sequence, whereas binding to ERα or 
LRH1 LBDs required the sequence SXLXXML, which more resembles the LXXLL signature 
motif. These differential requirements for docking with different NR LBDs suggest that 
cofactor motifs have co-evolved with NR LBD sequences to achieve selective interactions. 
Thus, conserved alpha helical motifs present in NR cofactors have evolved features that 
accommodate their selective binding to different subsets of NRs within the superfamily. 
DISCUSSION 
We have identified novel sequence motifs in the developmental co-repressor BCL11A that 
facilitate its selective interactions with members of the NR2E/F subfamily. These motifs, 
RID1 and RID2, bear resemblance to the LXXLL and LXXXLXXXI/L canonical motifs found 
in NR coactivators and corepressors, respectively. The BCL11A motifs are highly selective 
persistent expression of the γ-globin genes in adults, which were later shown to function as 
composite COUP-TFII /GATA binding sites (53). More recently, it has been reported that a 
non-coding sequence in the globin locus termed Bgl3 shows co-expression with γ-globins 
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locus contains binding sites for COUP-TFII, confirmed in EMSA and chip qPCR assays, 
suggesting Bgl3 transcription is regulated by this factor. Indeed, using the K562 
erythroleukemia cell line which contains only very low levels of BCL11A (Supplemental 
Fig.S5), we showed that exogenous BCL11A-XL can repress expression of the Bgl3 and γ-
globin genes, and that this is dependent on the functionality of the RID1 and RID2 motifs. 
These results indicate that interaction of BCL11A and COUP-TFII proteins is important for 
regulation of transcription within the globin locus. However, understanding the precise nature 
of these functional interactions is challenging, given that both factors may bind DNA/ 
chromatin independently, co-dependently or via associations with a complex network of 
1 
2 
3 (40). Moreover, both of these transcripts have been shown to be regulated by BCL11A 
4 
5 (13,40), although the function of the Bgl3 lncRNA remains to be determined. We have shown 
6 
7 here that similar to COUP-TFII-dependent regulation of the γ-globin genes (37,42), the Bgl3 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
2 8 other transcription factors (GATA1/2, SOX6, NF-Y) and co-repressors (NuRD, HDACs, 
29 
3 0 SIRT1, BCL6, Co-REST, NCoR) at globin gene regulatory sites , as shown schematically in 
31 
3 2 Fig. 6. Further studies will be required to determine the precise mechanisms involved. 
33 
3 4 TLX is a key stem cell fate regulator in the developing forebrain and eye (45,54). In 
35 
36 adult mice, TLX is expressed in the subventricular zone of the lateral ventricle and 
37 
38 subgranular layer of the dentate gyrus, both of which are regions associated with 
39 
40 neurogenesis (45,55). Consistent with in situ hybridisation studies on BCL11A transcripts 
41 
42 (24), we detected substantial expression of BCL11A-XL and L isoforms in the hippocampus 
43 
44 and cortex, and to a lesser extent in striatum (Fig. 3C&D). Moreover, we were able to 
45 
46 demonstrate that TLX and BCL11A proteins can be co-immunoprecipitated from extracts of 
47 
48 adult mouse cerebral cortex (Fig. 3E). This suggests that BCL11A may function as a 
49 
50 corepressor in TLX-mediated gene regulation in adult neuronal tissues. While genes that are 
51 
52 regulated by TLX/BCL11A remain to be identified, a previous study has shown that TLX can 
53 
54 
55 
56 
57 
58 23 
59 
60 
activate the RARβ2 promoter in response to ATRA (35). Reporter assays confirmed that 
Nucleic Acids Research Page 24 of 42 
1 
2 
3 TLX-mediated activation of the RARβ2 reporter gene in response to ATRA is repressed by 
4 
5 BCL11A to a similar extent as observed for COUP-TFII (Fig. 1F&G). 
6 
7 
8 
9 
10 
11 
12 
13 
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16 
17 
18 
19 
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21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
3 6 Both TLX and PNR have been reported to bind the Atrophin/RERE proteins that 
37 
3 8 function as transcription corepressors (50,51). Sequence alignments revealed that the 
39 
4 0 F/YSXXLXXL/Y motifs identified in BCL11A show partial similarity to a motif defined in 
41 
42 Atrophin/RERE proteins that mediates binding to TLX (Fig. 5A), termed the ATRO box (50). 
43 
44 Although saturation mutagenesis to define the ATRO box remains to be determined, it has 
45 
46 been shown that the sequence LXXL is required for association of Atrophins with TLX (50). It 
47 
48 remains to be established whether Atrophins are selective for PNR and TLX, or whether 
49 
50 atrophins can form complexes with COUP-TFs or other NRs. The RNA helicase Ret-
51 
52 CoR/DHX30 was isolated in a yeast two-hybrid screen of human brain cDNAs for PNR-
53 
54 binding proteins (57). Like atrophins, Ret-CoR is a component of a HDAC complex, which 
55 
56 was shown to act as a corepressor for GAL4-PNR-mediated transcription. The interaction of 
57 
58 24 
59 
60 
PNR expression in adult mammalian tissues is confined to photoreceptors in the 
retinal epithelial layer. Knockout studies have shown that PNR suppresses cone gene 
expression in photoreceptors, thus committing precursor cells to the rod lineage. PNR acts in 
conjunction with cone rod homeobox (CRX) and neural retina leucine zipper (NRL) to 
regulate rod and cone gene expression in a cell-specific manner, and appears to direct both 
positive and negative regulation (56). The mechanism by which this is achieved, and the 
cofactors that are involved remain unclear, although it has been reported that PNR can 
recruit Atrophins (51) and the Ret-CoR corepressor complex (57). Our findings indicate that 
PNR can also interact directly with BCL11A-XL, as demonstrated by yeast two-hybrid, in 
vitro studies and in transfected cells (Figs. 1&3). However, as we did not detect expression 
of BCL11A -L or XL isoforms in the eye (data not shown), it remains to be established 
whether coexpression of BCL11A and PNR occurs in other tissues, such as in the 
developing embryo. Alternatively, it is possible that PNR interacts with BCL11B or other 
proteins containing RID1-related motifs. 
Page 25 of 42 Nucleic Acids Research 
1 
2 
3 Ret-CoR with PNR was reported to be dependent on two copies of the sequence (LXXVI) 
4 
5 (57), which has similarity to CoRNR box and ATRO box motifs. However, it is not been 
6 
7 established if this protein can bind other NRs. Interestingly, while Ret-CoR/PNR complexes 
8 
9 were shown to occur in the developing retina, expression of Ret-CoR in adult retinal tissues 
10 
11 was very low (57). Thus interactions of RetCoR and BCL11A/B with PNR may be restricted 
12 
13 to embryonic development. 
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43 
4 4 to facilitate both RID1 and RID2, V224 appears to be essential for RID2 only. These results 
45 
4 6 are suggestive of subtle differences in how RID1 and RID2 motifs dock with the COUP-TFII 
47 
4 8 LBD, possibly involving different contacts with cofactor binding groove to displace the AF2 
49 
50 helix. This is reminiscent of the different binding mechanisms observed for the interaction of 
51 
52 the ID1/CoRNR1and ID2/CoRNR2 motifs with the RAR LBD (59). Structural studies will be 
53 
54 required to reveal how RID1 and RID2 sequences dock with NR2E/F LBDs. 
55 
56 
57 
58 25 
59 
60 
Biochemical and structural studies have revealed that NR LBDs undergo 
conformational changes in response to agonist/antagonist binding, and that these changes 
regulate interactions with coactivators and corepressors. Crystal structures of apo- and holo-
receptor LBDs have demonstrated the conformational flexibility of the AF2 helix in ‘activating’ 
or ‘repressive’ conformations of the LBD, and this positioning is thought to facilitate the 
docking of coactivators and corepressors (reviewed in (53,58)). Both coactivator (LXXLL) 
peptides and repressor peptides occupy the same docking site, suggesting a mutually 
exclusive mechanism of interaction. Among the NR2E/F subfamily, only the crystal structure 
of the unliganded COUP-TFII monomer has been determined, and this shows the AF2 helix 
occupying the cofactor binding pocket on the LBD surface (49). Based on other LBD 
structures, this autoinhibitory conformation is likely to be refractory to cofactor binding. Thus, 
the question remains as to how corepressors and coactivators dock with COUP-TFII LBD. 
Our mutagenesis assays indicate that residues in Helix 3 that help to accommodate the AF2 
helix in the ‘auto-inhibited’ LBD are involved in the binding of BCL11A while F221 is required 
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1 
2 
3 Although COUP-TFs can synergise with coactivators to activate transcription in 
4 
5 reporter assays (49) evidence for direct interactions of the COUP-TFs with the coactivators 
6 
7 is lacking. In our hands, COUP-TFII LBD binding to full length proteins or LXXLL peptides 
8 
9 derived from SRC1 or MED1/TRAP220 is not robust enough to be detected in Y2H or GST 
10 
11 pulldown assays (Fig. 3A and data not shown). Thus, the mechanism by which COUP-TFII 
12 
13 activates transcription remains to be determined. It is possible that COUP-TFs may recruit 
14 
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34 
35 
36 
37 
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39 
40 
41 
42 
43 
4 4 known to interact with both GATA and COUP-TFII proteins to regulate globin gene 
45 
4 6 expression in haematopoietic tissues (60,61). Intriguingly, the C-terminal sequence 848-
47 
4 8 1152, which mediates interaction with COUP-TFII comprises a FSXXLXXL motif (Fig. 5A). 
49 
50 Further studies will be required to determine whether RID1/RID2 motifs are unique to the 
51 
52 BCL11A/B and NSD1 proteins or are more widespread amongst cofactors for COUP-TFs, 
53 
54 TLX and PNR. 
55 
56 
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coactivators indirectly via heterodimer partners, or that the observed positive effects of 
COUP-TFII on transcription are due to derepression mechanisms, such as sequestering 
corepressors away from target genes. Although the NR-binding LXXLL motifs in SRC1 (Fig. 
3) and MED1/TRAP220 (data not shown) appear to interact exclusively with ‘activating’ NRs, 
we have shown here that the NR binding motif of NSD1 has features that can promote its 
binding to both ‘activating’ and ‘repressive’ NRs. Interestingly, the failure of PNR to bind 
NSD1 FSXXLXXL motif, indicates a more specific sequence requirement consistent with the 
mutagenesis data in Fig. 4C. It remains to be investigated whether NSD1 forms complexes 
with NR2E/Fs in vivo, in particular in brain where both proteins are highly expressed. 
In addition to BCL11A/B and NSD1, F/YSXXLXXL/Y motifs are found in other 
proteins including NRs, NR cofactors and other gene regulatory proteins (see 
Supplementary Fig. S7). It remains to be established if these motifs can promote direct 
interactions with NR2E/F subfamily members, although for some there is previous evidence 
that such complexes exist. For example, the zinc finger repressor Friend of GATA (FOG2) is 
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1 
2 
3 In summary, we have defined a new signature motif selective for the NR2E/F 
4 
5 subfamily and highlighted previously unknown roles for BCL11A/B and NSD1 proteins in the 
6 
7 gene regulation by COUP-TFs, TLX and PNR. Moreover, our study provides new insights 
8 
9 into how subtle variations in short sequences at the interface of NR/cofactor complexes 
10 
11 determine selectivity. 
12 
13 
14 
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FIGURE LEGENDS 
FIGURE 1 . Novel signature motifs required for interaction of BCL11A-XL with COUP-
TFII and related NRs. 
(A) Yeast two-hybrid interaction assays mapping the minimal sequences in BCL11A-XL that 
are required to bind the COUP-TFII LBD. LexA DBD-BCL11A fusion constructs were 
expressed in the L40 reporter strain either alone (black bars) or in conjunction with AAD-
COUP-TFII LBD (grey bars). Reporter activity in cell-free extracts is measured as β-
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25 
26 
2 7 galactosidase activities (nmoles /min/mg protein). The data shown represent the mean of 
28 
2 9 triplicate assays, and error bars represent the standard error of the mean. A schematic 
30 
3 1 representation of BCL11A-XL protein is shown above the chart: black boxes represent 
32 
3 3 Kruppel-like zinc fingers; white boxes represent the minimal COUP-TFII-interacting regions 
34 
35 RID1and RID2. Amino acid numbers for the boundaries of RID, RID2 and zinc finger motifs 
36 
37 are indicated. (B) Yeast two interactions of AAD-COUP-TFII LBD with RID1, RID2 and 
38 
39 mutants thereof. (C) Alignment of BCL11A RID1 and RID2 sequences conserved in human, 
40 
41 mouse, zebrafish, frog (Xenopus laevis), fly (Drosophila melanogaster) and tick (Ixodes 
42 
43 scapularis). (D) GST pulldown experiment showing interaction of in vitro translated 35S-
44 
45 labelled FLAG-BCL11A-XL wild type or RID1/RID2 double mutant (L319A/Y656A/W659A) 
46 
47 with GST or GST-NR LBDs. For GST-PPARγ, binding was assessed in the presence of 1µM 
48 
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58 32 
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of the agonist roziglitazone (+) or vehicle (-). (E,F,G) Reporter assays in transfected U2OS 
cells showing effect of BCL11A proteins on retinoic acid (ATRA)-induced activation of a 
RARβ2-luciferase. Reporter values were obtained after 24 hours exposure of transfected 
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for BCL11 A-mediated repression of human y-globin and Bgl3 genes. 
(A) Schematic representation of the human beta globin locus (not to scale) with boxes 
indicating the locus control region (LCR) and the embryonic (s), foetal (Gy and Ay) and adult 
(8 and p) globin genes. The putative lncRNA Bgl3 and the pseudogene HBBP1 are also 
represented. Approximate regions amplified by PCR are indicated by lines over the boxes, 
1 
2 
3 cells to 10-6 M ATRA (grey bars), or vehicle (black bars). Mean luciferase values from 
4 
5 triplicate assays are shown, and error bars indicate the standard error of the mean. 
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9 FIGURE 2. COUP-TFII binding sites in the Bgl3 locus, and requirement of RID1/RID2 
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2 2 including DNAse-I hypersensitive sites in the LCR (HS2 and HS3) and downstream region 
23 
24 (HS1-3’). (B) Relative expression of Bgl3 and γ-globin transcripts (relative to GAPDH) in 
25 
26 DOHH2 and K562 cells. The data are shown on a log scale as averages of triplicates and 
27 
28 the error bars represent the standard deviations. (C) Chromatin IP qPCR revealing detection 
29 
30 of BCL11A proteins at the HS3 site in the globin LCR in DOHH2 cells, but not K562 cells. 
31 
32 Control (no antibody) is shown for comparison. The data shown is a representative 
33 
34 experiment showing the average of triplicates, with error bars indicating standard deviations. 
35 
36 (D) ChIP qPCR detection of BCL11A or COUP-TFII proteins at the LCR HS2 and HS3 sites, 
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the γ-globin promoter, the Bgl3 sequence, and the HS1-3’ site. (E) Electrophoretic mobility 
shift assays (EMSA) indicating the presence of COUP-TFII binding sites within the human 
Bgl3 sequence. Double stranded DNA probes (end labelled with γ32P) were incubated with 
cell-free extracts of HEK293 cells expressing recombinant Nuclear Receptor or BCL11A-XL 
proteins, or mock transfected as indicated (as described in Materials & Methods). The Bgl3 
transcribed region is represented schematically and the relative positions of the probes used 
in the EMSA experiments are indicated. Free probes and specific COUP-TFII/DNA 
complexes are indicated on the image. The sequences of the probes which showed specific 
complex formation with COUP-TFII are represented below the gel image. Putative HRE half 
sites are overlined and sequence changes made to disrupt these half sites in ‘mutated’ 
58 33 
59 
60 
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3 probes are indicated. (F) EMSA supershift experiment to validate of the identity of COUP-
4 
5 TFII containing complexes using a COUP-TFII specific antibody as described in Materials 
6 
7 and Methods. (G) Comparison of the abilities of COUP-TFII, TLX or PNR proteins to bind the 
8 
9 indicated Bgl3 probes. (H) RT-qPCR experiments indicating the effects of GFP, GFP-
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3 6 mRID1/2 (L319A/Y656A/W659A), mRID1 (L319A) or mRID2 (Y656A/W659A). FLAG-tagged 
37 
3 8 proteins were immunoprecipitated with anti-FLAG beads and associated proteins detected 
39 
4 0 using the indicated antibodies. (C) Immunohistochemical staining of BCL11A proteins 
41 
42 showing strong staining in the pyramidal cell layer (Py) extending from CA1 to the dentate 
43 
44 gyrus (DG). Right panel shows magnification of the boxed region showing nuclear staining of 
45 
46 BCL11A. (D) Immunodetection of TLX and BCL11A proteins in mouse brain tissue 
47 
48 homogenates as indicated. (E) Co-immunoprecipitation of endogenous TLX and BCL11A 
49 
50 proteins from adult mouse cerebral cortex tissue extract. 
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BCL11A and GFP-BCL11A(RID1/2)mut on endogenous γ-globin and Bgl3 expression 
(relative to GAPDH) in transfected K562 cells. The experiment was performed in triplicate 
with error bars indicating standard deviations, and p values indicated (* p<0.05) (** p<0.005). 
FIGURE 3. Selective Nuclear Receptor binding by BCL11A RID1 and RID2 motifs. 
(A) Yeast two-hybrid interactions of VP16 AAD-fused NR-LBDs with LexA DBD-fused SRC1 
NID 489-827 (containing LXXLL motifs), or BCL11A RID1 and RID2 sequences as indicated. 
The results shown represent the mean reporter (β-galactosidase) activity ± standard error of 
triplicate experiments. Cognate ligands if known were added (grey columns), whereas 
vehicle only or no ligand is represented by black columns. (B) Co-immunoprecipitation of 
recombinant NR/BCL11A complexes. HEK293 cells co-transfected with COUP-TFII, HA-TLX 
or HA-PNR expression vectors in combination with FLAG-BCL11A-XL (WT), or the mutants 
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3 FIGURE 4. Probing the binding interface between NR2E/Fs and BCL11A 
4 
5 COUP-TFII LBD Helix 3 residues facilitate docking of RID1 and RID2: (A) Cartoon 
6 
7 representation (left panel) of the COUP-TFII LBD (PDB: 3CJW) (49) generated using PyMol 
8 
9 open source molecular visualisation tool. The AF2 helix is shown in yellow. Key residues in 
10 
11 Helix 3 (magenta) and Helix 5 (orange) are indicated. Right panel shows a surface 
12 
13 representation of the COUP-TFII LBD complex highlighting the exposed phenylalanine F221 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
4 1
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(red) and R228 (blue) which hydrogen bonds to the AF2 helix. In this view, V224 is buried 
beneath the AF2 helix. (B) Yeast two-hybrid interactions of LexA-BCL11A RID1 and LexA-
BCL11A RID2 with AAD-COUP-TFII LBD wild type or mutant proteins as indicated. The right 
panel shows the effect of these mutations on heterodimer formation with LexA COUP-TFII 
LBD. The results shown represent the mean reporter (β-galactosidase) activity ± standard 
error of triplicates. Differential sequence requirements for binding of RID1 and RID2 to 
NR2Es and NR2Fs: Yeast two-hybrid interactions of (C) LexA-BCL11A RID1 and (D) LexA-
BCL11A RID2 alanine scan mutant series in combination with AAD-NR LBD constructs as 
indicated. The results shown represent the mean reporter (β-galactosidase) activity ± 
standard error of triplicates. The sequence motif required for the binding of each NR LBD is 
indicated below the graph. 
(A) Sequence alignment showing the presence RID1/RID2 and ATRO box sequences in 
NR2-binding cofactors. The sequences are based on human Refseq entries in NCBI Protein 
or Gene databases. Conserved FS and L residues are shaded. Predicted alpha-helicity of 
the BCL11A RID1 sequence is shown above the alignment. (B) Yeast two-hybrid interactions 
of LexA DBD-fused NSD1 790-818 with AAD-NR-LBD constructs as indicated. Cognate 
ligands if known were added (grey columns), whereas vehicle only or no ligand is 
represented by black columns. The results shown represent the mean reporter (β-
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the NSD1 NID+L region (790-818) is indicated, and the sequence motif required for binding 
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3 galactosidase) activity ± standard error of triplicate experiments. (C) Binding of LexA NSD1 
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5 790-818 wild type or mutants to AAD-TLX, AAD-ERα, AAD-LRH1 LBDs. The sequence of 
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 to different NR LBDs is indicated above the bar charts. 
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Figure 6 
Schematic model showing possible modes of recruitment of BCL11A to regulatory sites in 
the globin locus, and the formation of functional complexes with COUP-TFII; A) Direct, 
independent recruitment of both factors to DNA sequences or chromatin; B) co-dependent 
recruitment through protein-protein interactions mediated by F/VSXXLXXL/Y motifs; C) 
Multivalent interactions between different factors assembled in situ; D) Long distance 
interactions involving transcription factors and chromatin regulator complexes e.g due to 
chromatin looping. 
SUPPLEMENTARY DATA 
Supplementary data are available at NAR Online: Supplementary Figures S1-S7 and 
Page 37 of 42 Nucleic Acids Research 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
URE 1 
28 
BCL11AXL 
29 
RID1 
30 310-325 
31148-71 172-193 379-427 
32 
B 
AAD-COUPTFII 
RID2 
651-670 
Zinc finger 
RID1 / RID2 
744-823 
E835 
33 
2 1 2 - 2 9 0 = 
3412-295 
212-329 
37283-376 
3 8 295-376 
313-376 
3926-376 
40283-329 
302-325 
41306-325 
42310-325 
= 
C=LexA-BCL11A + AA 
MLexA-BCL11A 
LexA-RID1 
302-325 
310-325 
F315A 
S316A 
R317A 
L319A 
R320A 
L322A 
LexA-RID2 
651-670 
V655A 
Y656A 
S657A 
Q658A 
W659A 
L660A 
G662A 
Y663A 
0 400 800 1200 1600 
β-Galactosidase Activity (nmol/mg/min) 
AAD-COUPTFII 
0 1000 2000 3000 
-Galactosidase Activity (nmol/mg/min) 
C FSRRLREL 
PMAMEPPAMD FSRRLREL 
PMAMEPPAMD FSRRLREL 
RID1 
Human 305 
Mouse 305 
Fish 272 PIPMDPPAMD 
Frog 372 PLAMEPPAMD 
Fly 599 SLKLEPQQ 
Tick 232 GLSLEP-Q 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56E 
57 
58 
59 
60 
0 1000 2000 3000 
β-Galactosidase Activity (nmol/mg/min) 
RID2 
Human 646 
Mouse 646 
594-707 
594-687 
594-670 
611-641 
651-707 
651-687 
651-670 
C = LexA-BCL11A + AAD COUPTFII 
M L e x A - B C L 1 1 A 
a D 
Fish 
Frog 
Tick 
YSQ-WLAGY 
PAAMPNTENV YSQ-WLAGY AASRQLKDPFLTF 
PAAMPNTENV YSQ-WLAGY AASRQLKDPFLTF 
PNTENV YSQ-WLAGY AASRQLKDPF 
PNTENV YSQ-WLAGY AASRQ 
642 TPTI  
588 ASAM  LKEPFLTF 
388 KIGLTNIQQY YSEAYRQAL EESGGLRLLGAFD 
0 500 1000 1500 2000 2500 
β-Galactosidase Activity (nmol/mg/min) 
WT 
mRID1/2 
RARβ2 PROMOTER 
1 200 
1000 
800 
600 
400 
200 
0 
COUPTFII 
Vehicle 
1 μ M A T R A 
RARβ2 PROMOTER G 
COUPTFII 
BCL11AXL WT 
BCL11AXL mRID1/2 
BCL11AXL mRID1 
BCL11AXL mRID2 
Vehicle 
1 μM ATRA 
600 
500 
400 
300 
200 
100 
0 
Roziglitazone 
RARβ2 PROMOTER 
Vehicle 
1 μM ATRA 
TLX (ng) 
BCL11AXL 
100 500 100 
+ 
F 
Nucleic Acids Research Page 38 of 42 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
FIGURE 2 
A HS3 HBG1 HBBP1 
A HS2 HBE1 HBG2 Bgl3 
ttffl- - H -
Gy Ay 
10 -
1.0E-1 
1.0E-2 
1.0E-3 
1.0E-4 
1.0E-5 
1.0E-6 
1.0E-7 
• DOHH2 
K562 " 
1 
• i 
0.14 
-0.12 
D No Antibody 
• BCL11A 
COUPTFI I 
t 
No BCL11A HS3 HS2 HBG2 Bgl3C 3'HS1 
Bg!3g 
128-151 
151-182 
• 128-182mut 
739-763 
• 763-795 
- 739-795mut 
128-151 151-182 128-182mut 739-763 763-795 739-795mut 
Bgl3 Bgl3 
739-763 128-151 
Mock . 5 - - - 5 - -
COUP-TFII . . 5 5 . - 5 5 
anti-COUP-TFII . . . + + 
COUP-TFII/DNA 
complex 
G 
128-151 5'-GACATGACCTGAAGTTTCCTCTGAGGCCAGTC-3' 
739-763 5'-CAAATGACCTAATGCCCAGCACGGGCCACGGAA-3' 
Bgl3 128-151 Bgl3 739-763 
Mock . 2 5 1 0 
COUP-TFII 2 5 10 - - -
TLX . 2 5 10 
PNR - - - - - - - - - - 2 5 10 
X 
< 
P3 o 
~ f 
c 
•«5 
CD 
fet 
3.5, « * 
\ 2 , J 
H * 1.5-1 '—I 1 
1 I 
' • 
°-5 I - l I 0 1 * " " 
5.5 
4.5 
4 
3 
2.5 
2 
1.5 
1 
0 
** 
I 
* 1 r~J i 
••1 
^ 
/ -J-
FIGURE 2 
2 8 2 X 3 9 8 M M ( 3 0 0 X 3 0 0 D P I ) 
Page 39 of 42 Nucleic Acids Research 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
FIGURE 3 
A 
NR1A2 
NR1B1 
NR1C3 
NR1I1 
NR2B1 
NR3A1 
NR3C4 
NR1D2 
NR1F1 
NR1F2 
NR2A2 
NR2C1 
NR2C2 
NR2E1 
NR2E3 
NR2F1 
NR2F2 
NR2F6 
NR3B1 
NR4A1 
NR4A2 
NR5A2 
NR6A1 
NR0B1 
NR0B2 
R LBD 
PPARv 
VDR RXRa 
AR 
Rev-erbp 
RORa 
RORp 
HNF4Y 
TR2 
TR4 
NURR77 
NURR1 
GCNF 
DAX-1 
SHP 
LexA-SRC1 NID LexA-RID1 310-325 LexA-RID2 651-670 
+ Ligands (1µM) 
Vehicle Control 
0 1000 2000 3000 0 1000 2000 3000 0 1000 2000 3000 
β-Galactosidase Activity (nmol/mg/min) 
a - B C L 1 1 A 
Flag-BCL11AX 
WB: α-BCL11AXL 
WB: α-COUP-TFII I 
WB: α-BCL11AXL 
WB: α-COUP-TFII i 
l-« Flag-BCL11 A 
XL 
-* COUP-TFII 
-* Flag-BCL11AXL 
^m — « - 4 C O U P - T F I I 
WB: α-BC11AXL 
WB: α-HA 
WB: α-BC11A 
XL 
WB: α-HA 
i -* Flag-BCL11A 
XL 
* -* HA-TLX 
•
- *F lag -BCL11A 
XL 
I -* HA-TLX 
WB: α-Flag 
WB: α-HA 
WB: α-Flag 
WB: α-HA 
-« Flag-BCL11A 
XL 
^ HA-PNR 
- *F lag -BCL11A 
XL 
•** HA-PNR 
P y £ ^ 
BCL11A XL 
BCL11A L 
Input 
(10%) 
WB:BCL11A 
WB:TLX 
WB: β-Actin 
B 
C D E 
IP 
TLX 
Nucleic Acids Research Page 40 of 42 
1 
F I G U R E 4 
2 
3 
4 A 
5 
6 
7 
8 
9 
10 
1 1 
12 
13 
14 
15 
16 
17 
18 
19 
B 
20 
2 1 
22 
23 
24 
25 
26 
27 
28 
29 
30 
3 1 
32 
33 
34 
35 
C 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
D 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
F221, ' ^ , J J 
AF2 
38 
UP-TF 
WT 
F221A 
V224A 
I238A 
V242A 
R246A 
I I LEXA-BCL11A R I D 1 LEXA-BCL11A R ID2 LEXA-COUPTFII L B D 
1000 2000 0 1000 2000 3000 0 
β-Galactosidase Activity (nmol/mg/min) 
200 400 600 
L E X A - R I D 1 A A D - C O U P T F I 
WT 
F315A 
S316A 
R317A 
L319A 
R320A 
L322A 
A A D - E A R 2 A A D - T L X A A D - P N R 
LexA-RID1 + AAD-NR 
LexA-RID1 + AAD 
1000 2000 0 1000 20000 1000 2000 0 1000 2000 3000 
β-Galactosidase Activity (nmol/mg/min) 
FSXXLXXL SXXLXXL FXXXLXXL FXRXLRXL 
L E X A - R I D 2 A A D - C O U P T F I A A D - E A R 2 A A D - T L X 
WT 
V655A 
Y656A 
S657A 
Q658A 
W659A 
L660A 
G662A 
Y663A 
LexA-RID2 + AAD-NR 
LexA-RID2 + AAD 
0 1000 2000 30000 1000 2000 3000 0 1000 2000 3000 
β-Galactosidase Activity (nmol/mg/min) 
VYSXWLXXY VXXXWLXXY YXXXLXXY 
0 
0 
Page 41 of 42 Nucleic Acids Research 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
FIGURE 5 
BCL11A 
BCL11A 
BCL11B 
BCL11B 
NSD1 
FOG2 
RetCOR 
RetCOR 
ATN1 
RERE/ATN2 
310 
651 
358 
703 
798 
927 
48 
240 
874 
1244 
PPAMD 
NTENV 
SPAMD 
PSENV 
EPDYK 
PNGNL 
KEFPQ 
TQFPL 
PYLGP 
PYIGP 
FSXXLXXL 
FSRRLREL 
YSQWLAGY 
FSRRLREL 
YSQWLVGY 
FSTLLMML 
FSSHLATL 
PKNLLNSV 
PKNLLAKV 
DTPALRTL 
DTPALRTL 
AGNTSSPP 
AASRQLKD 
AGNSSTPP 
AASRHFMK 
KDMHDSKT 
QGLKVFSE 
IGRALGIS 
IQIATSSS 
SEYARPHV 
SEYARPHV 
330 
671 
378 
723 
818 
947 
68 
260 
894 
1264 
NR Binding 
NR2E/F 
NR2F;NR2E1 
NR2E/F 
NR2F;NR2E1 
NR1ABC;2B;3C 
NR2F2 
NR2E3 
NR2E3 
NR2E1 
NR2E1 
C 
LexA-NSD1 790-818 
WT 
Y801A 
K802A 
F803A 
S804A 
L806A 
L807A 
M808A 
M809A 
L810A 
K811A 
D812A 
AAD-TLX 
AAD 
m AAD-ERα + 1μM E2 
• AAD-ERα + Vehicle 
AAD-LRH1 
AAD 
0 500 1000 1500 2000 0 1000 2000 3000 0 400 
β-Galactosidase Activity (nmol/mg/min) 
800 1200 
FSXLLXML SXLXXML SXLXXML 
FIGURE 6 
Nucleic Acids Research Page 42 of 42 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
COUP-TFII 
BCL11A 
DNA/chromatin–dependent 
BCL11A 
SOX6 
GATA1/ 
COUP-TFII 
Multivalent Interactions 
BCL11A 
COUP-TFII 
Chromatin and TF-dependent 
NFY BCL11 
NURD; Co-REST;NCOR 
OX6 
J COUP-TFII 
Long distance interactions 
LCR looping 
SUPPLEMENTAL DATA 
FIGURE S1 
Expression of LexA-BCL11A fusion constructs in yeast 
Western blots were used to confirm the expression of the LexA-BCL11A fusion proteins 
used in this study, using anti-LexA antibody as described in the Materials & Methods. In all 
cases we were satisified that the estimated molecular weight of the detected constructs was 
as expected, and that any differences in expression levels were not sufficient to account for 
changes in reporter activities due to Y2H interaction. If possible, related constructs were run 
on the same blot for comparison. However, if composite figures are shown, this is 
emphasised by spacing apart of images. 
Fig S1A: RID1 deletion mapping constructs 
Fig. S1B RID2 deletion mapping constructs 
Fig. S1C RID1 Substitution Mutations 
Fig. S1D RID2 Substitution Mutations 
LexA-BCLIIA 
iiiiiifi / 
Anti-LexA DBD 
FIGURE S2 
A&B. Expression and Activity of AAD-NR LBD fusion constructs in yeast 
(A) Western blots were used to confirm the expression of the AAD (VP16 411-490)-NR LBD 
fusion proteins in S.cerevisiae L40 cell-free extracts, using anti-VP16 antibody as described 
in the Materials & Methods. In all cases we specifically detected recombinant proteins of the 
correct estimated molecular weight. To assess whether these recombinant proteins show 
any inherent ability to activate the lacZ reporter gene, AAD-NR LBD constructs were 
cotransformed with LexA DBD alone. As shown in (B), activation of the reporter due to to 
LexA alone in combination with AAD or any of the 25 AAD-NR constructs was negligible. 
Reporter activation due to interaction of AAD-NR LBDs with LexA-SRC1 NID is shown for 
comparison (SRC1 data already shown in Fig. 2A) 
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C. Western blot detection of AAD-COUP-TFII LBD mutants 
Western blots detecting AAD-COUP-TFII LBD substitution mutants in S.cerevisiae L40 cell-
free extracts, using anti-VP16 antibody as described in the Materials & Methods. 
Quantitation relative to the highest expression level (set to 1) was performed using the 
Image j analysis tool. 
D. Interaction of COUP-TFII with RID1 and RID2 is dependent on the AF2 helix 
Yeast two-hybrid assays showing the effect of C-terminal deletions on the interaction of 
COUP-TFII LBD with the BCL11A RID1 and RID2 sequences. The A12 deletion refers to the 
AF2 helix A12 whereas A11 truncates helices 11 and 12, and A10 deletes helices 10,11,12 
as based on the reported structure (ref. 49). Western blot detection of the mutants is shown 
in the inset. 
FIGURE S3 
A. Oligonucleotide Probes used for EMSA experiments 
Sequences of the sense and antisense strand primers used in this study are listed below. 
Potential HRE half sites are underlined. Bases that have been mutated to disrupt HREs are 
highlighted in bold. 
Bgl3 Sequences 
+198/+231 
5’-TTCCGTGGCCCGTGCTGGGCATTAGGTCATTT-3’ 
3’-AAATGACCTAATGCCCAGCACGGGCCACGGAA-5’ 
+231/+255 
5’-TGTGTCTGGCACAGGCTTGATCTATA-3’ 
3’-TATAGATCAAGCCTGTGCCAGACACA-5’ 
+198/+255 
5’-TTCCGTGGCCCGTGCTGGGCATTAGGTCATTTGTGTCTGGCACAGGCTTGATCTATA-3’ 
3’-TATAGATCAAGCCTGTGCCAGACACAAATGACCTAATGCCCAGCACGGGCCACGGAA -5’ 
+198/+255 mutant 
5’-TTCCGTGGCCCGAACTGGAAATTAGGAAATTTGTGTCTGAAACAGGCTTGATCTATA-3’ 
3’- TATAGATCAAGCCTGTTTCAGACACAAATTTCCTAATTTCCAGTTCGGGCCACGGAA -5’ 
+812/+843 
5’-GACTGGCCTCAGAGGAAACTTCAGGTCATGTC-3’ 
3’-GACATGACCTGAAGTTTCCTCTGAGGCCAGTC -5’ 
+843/+867 
5’-CCTTTAATGGCCCTAAAACTCATTC-3’ 
3’-GAATGAGTTTTAGGGCCATTAAAGG-5’ 
+812/+867 
5’-GACTGGCCTCAGAGGAAACTTCAGGTCATGTCCTTTAATGGCCCTAAAACTCATTC-3’ 
3’-GAATGAGTTTTAGGGCCATTAAAGGACATGACCTGAAGTTTCCTCTGAGGCCAGTC-5’ 
+812/+867 mutant 
5’-GACTGGCCAAAGAGGAAACTTCAGGAAATGTCCTTTAATGGCCCTAAAACTCATTC-3’ 
3’-GAATGAGTTTTAGGGCCATTAAAGGACATTTCCTGAAGTTTCCTCTTTGGCCAGTC-5’ 
RAR02 COUP-TFII RE (DR8) 
5’-GGTGATGTCAGACTAGTTGGGTCATTTG-3’ 
5’-CAAATGACCCAACTAGTCTGACATCACC-3’ 
B. Primers used for Chromatin Immunoprecipitation qPCR 
Human y-globin (HBG2) promoter 
Fw 5’-CCTTGCCTTGACCAATAGCCTTGACAAGG-3’ 
Rev 5’-CACAAGCCTGTGGGGCAAGGTGA-3’ 
Bgl3 
Fw 5’-AGTGTTGGGGGAGAAGTGTG-3’ 
Rev 5’-AATGACCTAATGCCCAGCAC-3’ 
Globin LCR DNAse I hypersensitive site HS2 
Fw 5’- CTGTGTAACCTTCTAAGC -3’ 
Rev 5’- CAGATAGGAGTCATCACT -3’ 
Globin LCR DNAse I hypersensitive site HS3 
Fw 5’-ATAGACCATGAGTAGAGGGCAGAC-3’ 
Rev 5’-TGATCCTGAAAACATAGGAGTCAA-3’ 
Globin Locus 3’ HS1 
Fw 5’-TCTTCAGCCATCCCAAGACT-3’ 
Rev 5’-TGGTCTTTTCTGGACACCAC-3’ 
C. Primers used for Reverse Transcriptase qPCR 
Bgl3 
Fw 5’-GGGAACAGCCACAAACAAGAAAGA-3’ 
Rev 5’-AGCCAACCAGGAATTCAGCAGTT-3 
r-globin HBG1/2 
Fw 5’-CCATAAAGCACCTGGATGATC-3’, 
Rev 5’-ATCTGGAGGACAGGGCACTG-3. 
FIGURE S4 
COUP-TFII binding to RARp2 promoter 
A) EMSA assays showing binding of COUP-TFII to the COUP-TFII response element 
located within the RAR2 proximal promoter (Left panel; See Fig. S3A for probe sequence). 
Note that little or no change in mobility is observed by addition of BCL11A-XL protein (lanes 
3&4). COUP-TFII can also shift a larger (300bp) RARp2 promoter fragment (right panel). 
RAR(32 
-250/+50 
B) Expression of recombinant proteins for use in EMSAs 
Western blot detection of BCL11A-XL, COUP-TFII and TLX proteins using the 
antibodies indicated as described in the Methods. 
FIGURE S5 
A. Detection of BCL11A-XL proteins in leukaemia cell lines. 
DOHH2 HL-60 K562 U937 
kDa 
250 
180 
135 
100 
50 
BCL11A-XL 
Actin 
Western blots showing expression levels of BCL11A-XL and p-Actin controls in cell-free 
extracts of the indicated cell lines. Extracts were prepared as described in Materials & 
Methods, and approximately 50|ug of extract was loaded per lane and resolved on 8% SDS-
PAGE gel. The blot was incubated with Anti-BCL11A primary antibody for 3 hours at room 
temperature, followed by washing and incubation with secondary antibody as described in 
Methods. The lower portion of the blot was incubated with anti-Actin antibody, as a loading 
control. 
FIGURE S6 
A. Direct interaction of BCL11A-XL with Bgl3 sequences 
EMSAs were performed as described for Figure 2E to assess direct interaction of BCL11A 
with Bgl3 sequences. Both probes showed concentration-dependent mobility shifts, however 
the protein/DNA complexes were diffuse, indicating multivalent interactions, low sequence 
specificity or complex instability. In contrast BCL11A proteins did not appear to associate 
directly with the COUP-TFII binding sequence present in the RARb2 (See Fig. S4D). 
B. Assessment of COUP-TFII / BCL11A binding to Bgl3 DNA probes. 
EMSAs and antibody supershift assays were performed as described for Figure 2F. 
Although addition of FLAG-BCL11A-XL containing extract (but not control) resulted in the 
emergence of higher molecular weight bands COUP-TFII (compare lanes 4-6; 11-13), we did 
not observe a strong supershift with a-FLAG antibody (lane 7,14), in contrast to the a-
COUPTFII (lane 8,15). 
FIGURE S7 
(A) RID1 / RID2-Related Motifs in NR-Associated Proteins 
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(B) RID1 / RID2-Related Motifs in NRs 
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(A) Sequence alignments showing the occurrence of RID1/ RID2-related sequences in 
known NR-binding proteins or other proteins known to function in gene regulation. These 
sequences were identified using the Prosite Scan tool (www.expasy.org). Interactions with 
NR subtypes as recorded in NCBI Gene or protein interaction databases (e.g. BioGRID) are 
indicated. Reported interactions with atrophins are also indicated. Notably, the Androgen 
Receptor Interacting Protein ARIP4 (also termed RAD54L2) is a component of the SNF2 
family that is reported to function as a cofactor for AR (61). Like TLX, ARIP4 has been 
reported to interact with both Atrophin (62) and LSD1/CoREST complexes. The leucine 
zipper protein CREBZF (also known as SMILE or CREB/ATF) was reported to function as a 
corepressor for a number of NRs including NR3B3/ERRy, NR1I3/CAR and NR2A1/HNF4a 
(63,64). The region required to bind NRs in GST pulldown assays was mapped to the 
sequence 113-202 (63) which comprises a sequence resembling RID1, although it is not yet 
known if this protein binds NR2E/Fs. A number of other NR2E/F- interacting proteins 
reported in the literature such as the prospero-related protein PROX1 (65), MPPED1/2 (66), 
and eEF1D (66), harbour sequences that show weaker resemblance to the RID1, RID2 or 
ATRO motifs. It remains to be determined whether these sequences are involved in 
interactions with NR2E/s or other NRs. (B) Sequence alignments showing the occurrence of 
FSXXLXXL-related sequences in NRs. 
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